18.10.2021, 15:13
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
![[Bild: nic2x2.gif]](https://finviz.com/gfx/nic2x2.gif)
![[Bild: ADMPd091196283i.png]](https://finviz.com/publish/101821/ADMPd091196283i.png)
https://finviz.com/published_idea.ashx?t...091196283i
![[Bild: chart.ashx?t=admp&ty=c&ta=0&p=w&s=l]](https://charts2.finviz.com/chart.ashx?t=admp&ty=c&ta=0&p=w&s=l)
![[Bild: chart.ashx?t=admp&ty=c&ta=1&p=d&s=l]](https://charts2.finviz.com/chart.ashx?t=admp&ty=c&ta=1&p=d&s=l)
https://finviz.com/published_idea.ashx?t...091196283i